Skip to main content

Table 1 Assay consistency across studies

From: Characterization of two in vivo challenge models to measure functional activity of monoclonal antibodies to Plasmodium falciparum circumsporozoite protein

Dose (µg)Log 10 flux values for studies 1 to 7 using specified mAb
1—AB3112—AB3113—AB3114—AB3114—AB12455—AB3116—AB3117—AB311
MeanSDMeanSDMeanSDMeanSDMeanSDMeanSDMeanSDMeanSD
600Not applicable (N/A)5.380.057.400.115.310.265.400.135.310.05
3005.830.245.840.225.840.255.560.177.430.165.820.185.770.105.580.17
1006.410.206.570.176.530.356.460.217.320.086.010.216.250.236.160.15
307.060.117.050.12N/A7.030.117.470.066.840.126.520.156.640.16
10          6.950.12    
Untreated7.620.067.480.057.460.087.470.157.470.157.220.107.250.067.200.15
Naïve5.090.095.110.035.030.185.080.135.070.125.240.035.250.025.250.03
  1. Studies 1, 2, 3 did not include a 600-µg group. Only study five had a 10-µg group. Individual mouse total flux values were used to calculate geometric mean for each dose group
  2. mAb monoclonal antibody, SD standard deviation as estimated using a random effects model as described in methods